ライフサイエンスコーパス: 5-bromo-2'-deoxyuridine

1 s well as by incorporation experiments using 5-bromo-2'-deoxyuridine.

2 oliferation was assessed by incorporation of 5-bromo-2'-deoxyuridine.

3 en treated with retinoids and incubated with 5'-bromo-2'-deoxyuridine.

4 The rate of dehalogenation of 5-bromo-2'-deoxyuridine 5'-monophosphate (BrdUMP), a rea

5 5-Bromo-2'-deoxyuridine-5'-monophosphate (BrdU) immunohi

6 ain slices containing the VZ were exposed to 5-bromo-2'-deoxyuridine-5'-monophosphate (BrdU) in vitro

7 f the cofactor FAD and the substrate analog, 5-bromo-2'-deoxyuridine-5'-monophosphate (BrdUMP).

8 n, and proliferating cells were labeled with 5-bromo-2'-deoxyuridine-5'-monophosphate (BrdUrd) over 2

9 uction in the number of the thymidine analog 5-bromo-2'-deoxyuridine-5'-monophosphate- (BrdU) labeled

10 Cx43 expression and 24-hour 5-bromo-2'-deoxyuridine-5'monophosphate (BrdU) labeling

11 Using 5-bromo-2-deoxyuridine administration at P2, P11, P22, o

12 n of neuroblastoma cell differentiation with 5-bromo-2'deoxyuridine, all-trans-retinoic acid, or IFN-

13 Moreover, 7-aminoactinomycin D and 5-bromo-2'-deoxyuridine analysis showed indistinguishabl

14 ubjects with BSM cell proliferation by using 5-bromo-2'-deoxyuridine and cell counting and in the exp

15 Injection of 5-bromo-2'-deoxyuridine and immunocytochemistry showed t

16 In addition, studies with BrdU (5-bromo-2'-deoxyuridine)- and CFSE [5-(and 6)-carboxyflu

17 eration were assessed by labeling cells with 5-bromo-2'-deoxyuridine, and fecal microbial community c

18 te proliferation indices determined by using 5-bromo-2'-deoxyuridine; and measurement of the liver en

19 at synthesized DNA were identified with anti-5'-bromo-2'-deoxyuridine antibodies using secondary anti

20 ance of iESCs within the myocardium, whereas 5-bromo-2'-deoxyuridine assays revealed de novo in vivo

21 Using GFP to tag the newborn rods and by 5-bromo-2'-deoxyuridine birthdating, we demonstrate that

22 Using 5-bromo-2-deoxyuridine birthdating to identify newborn c

23 Treatment of cultured cells with 5-bromo-2'-deoxyuridine ((Br)dU) is known to result in t

24 oliferation was assessed by incorporation of 5-bromo-2'-deoxyuridine (BrdtJ).

25 ockout, and Cx50KI46 mice were injected with 5'-bromo-2'-deoxyuridine (BrdU) and lenses were dissecte

26 We used 5'-bromo-2'-deoxyuridine (BrdU) and retroviral methodolo

27 ells were labeled by subretinal injection of 5'-bromo-2'-deoxyuridine (BrdU) followed by immunohistoc

28 Using 5'-bromo-2'-deoxyuridine (BrdU) incorporation to label d

29 liver weight, histology, hepatocyte and BEC 5'-bromo-2'-deoxyuridine (BrdU) labeling, liver DNA cont

30 melanized cells that demonstrated diminished 5'-bromo-2'-deoxyuridine (BrdU) uptake and positive reac

31 To identify proliferating cells, 5'-bromo-2'-deoxyuridine (BrdU) was administered and det

32 The S-phase mitotic marker 5'-bromo-2'-deoxyuridine (BrdU) was administered at the

33 at various times after the administration of 5'-bromo-2'-deoxyuridine (BrdU), a marker of proliferati

34 tion, animals were continuously infused with 5'-bromo-2'-deoxyuridine (BrdU), starting at the time of

35 ation were assessed by in vivo labeling with 5'-bromo-2'-deoxyuridine (BrdU).

36 The analysis of the rate of accumulation of 5'-bromo-2-deoxyuridine (BrdU)-labeled splenic B cells i

37 At each time point, cells were pulsed with 5-bromo, 2-deoxyuridine (BrdU) fixed, and nuclei were st

38 At each time point, cells were pulsed with 5-bromo, 2-deoxyuridine (BrdU), fixed, and nuclei staine

39 Mathematical modeling of 5-bromo-2' deoxyuridine (BrdU) labeling dynamics demonst

40 ng cell nuclear antigen (PCNA) staining, and 5-bromo-2'-deoxyuridine (BrdU) analysis.

41 imilarly to metazoans in response to analogs 5-bromo-2'-deoxyuridine (BrdU) and 5-ethynyl-2'-deoxyuri

42 synthesis, which was monitored by measuring 5-bromo-2'-deoxyuridine (BrdU) and [3H]thymidine incorpo

43 rresponding fragility, we labeled cells with 5-bromo-2'-deoxyuridine (BrdU) and adopted an immunofluo

44 2 and 5 wk for viability by incorporation of 5-bromo-2'-deoxyuridine (BrdU) and by 3-(4,5-dimethylthi

45 Systemic injections of 5-bromo-2'-deoxyuridine (BrdU) and intraventricular inje

46 lls were labeled with the thymidine analogue 5-bromo-2'-deoxyuridine (BrdU) and their identity was de

47 e implanted with miniosmotic pumps releasing 5-bromo-2'-deoxyuridine (BrdU) as a cell proliferation m

48 All rats received 5-bromo-2'-deoxyuridine (BrdU) by intraperitoneal delive

49 Active caspase-3 and 5-bromo-2'-deoxyuridine (BrdU) double-labeled nuclei wer

50 5-Bromo-2'-deoxyuridine (BrdU) has been investigated as

51 hymidine and autoradiographic techniques and 5-bromo-2'-deoxyuridine (BrdU) immunocytochemistry were

52 Cell proliferation was determined by 5-bromo-2'-deoxyuridine (BrdU) immunohistochemistry and

53 in vivo was assayed using immunostaining for 5-bromo-2'-deoxyuridine (BrdU) in mouse LE cells after 2

54 s labeled with the cell proliferation marker 5-bromo-2'-deoxyuridine (BrdU) in the amygdala and DG th

55 liferation was measured by administration of 5-bromo-2'-deoxyuridine (BrdU) in the drinking water.

56 Mice were then given pulses of 5-bromo-2'-deoxyuridine (BrdU) in their drinking water,

57 ion were assayed by immunohistochemistry for 5-bromo-2'-deoxyuridine (BrdU) incorporation and by in s

58 tic increases in [methyl-(3)H] thymidine and 5-bromo-2'-deoxyuridine (BrdU) incorporation and in the

59 SisterC employs 5-bromo-2'-deoxyuridine (BrdU) incorporation during S-ph

60 in (130 nmol kg(-1)) significantly increased 5-bromo-2'-deoxyuridine (BrdU) incorporation in the DMNV

61 Hepatic cellular 5-bromo-2'-deoxyuridine (BrdU) incorporation increased f

62 Using 5-Bromo-2'-deoxyuridine (BrdU) incorporation to generate

63 ed significant G0/G1 arrest and reduction in 5-bromo-2'-deoxyuridine (BrdU) incorporation.

64 growth was assayed by formazan formation and 5-bromo-2'-deoxyuridine (BrdU) incorporation.

65 emistry, point-counting morphometry, and 6-h 5-bromo-2'-deoxyuridine (BrdU) incorporation.

66 to assess whether a single administration of 5-bromo-2'-deoxyuridine (BrdU) interferes with cell prol

67 The replacement of thymidine with 5-bromo-2'-deoxyuridine (BrdU) is well-known to sensitiz

68 Monocyte progenitors were 5-bromo-2'-deoxyuridine (BrdU) labeled in bone marrow, a

69 Rather, 5-bromo-2'-deoxyuridine (BrdU) labeling studies suggest

70 l 80% of cells were nondividing in a 72-hour 5-bromo-2'-deoxyuridine (BrdU) labeling study.

71 5-Bromo-2'-deoxyuridine (BrdU) labelling and retrovirus

72 present study, we have used a combination of 5-bromo-2'-deoxyuridine (BrDU) pulse labeling, intracell

73 Using these models, along with a 5-bromo-2'-deoxyuridine (BrdU) pulse-label strategy, we

74 PCs, we analyzed the cell cycle change using 5-bromo-2'-deoxyuridine (BrdU) pulse-labeling and DAPI (

75 omparison with the "gold standard" method of 5-bromo-2'-deoxyuridine (BrdU) staining using two behavi

76 We used 5-bromo-2'-deoxyuridine (BrdU) to identify and localize

77 or received one intraperitoneal injection of 5-bromo-2'-deoxyuridine (BrdU) to label progenitors in t

78 Proliferation was quantified by 5-bromo-2'-deoxyuridine (BrdU) uptake (10 mum).

79 d measured footprint area and proliferation (5-bromo-2'-deoxyuridine (BrdU) uptake) separately in mon

80 In some mice, after 41 hr of surgery, 5-bromo-2'-deoxyuridine (BrdU) was administered for BrdU

81 l proliferating cells the thymidine analogue 5-bromo-2'-deoxyuridine (BrdU) was injected after the fi

82 By using 5-bromo-2'-deoxyuridine (BrdU), a label-retaining cell p

83 fluorescent immunohistochemical detection of 5-bromo-2'-deoxyuridine (BrdU), a marker of granule cell

84 Nucleoside 5-bromo-2'-deoxyuridine (BrdU), after being incorporated

85 er a series of intraperitoneal injections of 5-bromo-2'-deoxyuridine (BrdU), animals received stereot

86 udies lymphocytes are typically labeled with 5-bromo-2'-deoxyuridine (BrdU), deuterium, or the fluore

87 ized cell populations are pulse-labeled with 5-bromo-2'-deoxyuridine (BrdU), fractionated according t

88 For example, the percentage of 5-bromo-2'-deoxyuridine (BrdU)-labeled cells in epitheli

89 very rapid turnover of NK cells, continuous 5-bromo-2'-deoxyuridine (BrdU)-labeling studies demonstr

90 Actually, OP3-4 enhanced the BMP-2-induced 5-bromo-2'-deoxyuridine (BrdU)-positive cell numbers at

91 l proliferation was assayed by labeling with 5-bromo-2'-deoxyuridine (BrdU).

92 in their incorporation of [3H]thymidine and 5-bromo-2'-deoxyuridine (BrdU).

93 te to the daughter strand readily labeled by 5-bromo-2'-deoxyuridine (BrdU).

94 d detection of the marker of DNA replication 5-bromo-2'-deoxyuridine (BrdU).

95 ghout the brain of an anuran amphibian using 5-bromo-2'-deoxyuridine (BrdU).

96 d late on day 5 with an intravenous pulse of 5-bromo-2'-deoxyuridine (BrdU).

97 ate cell proliferation, the exogenous marker 5-bromo-2'-deoxyuridine (BrdU, 200mg/kg, ip) was adminis

98 llowing drug treatment, the thymidine analog 5-bromo-2'-deoxyuridine (BrdU; 200 mg/kg, i.p.) was admi

99 sitive for both the neuronal marker NeuN and 5-bromo-2'-deoxyuridine (BrdU; a marker for proliferatin

100 rker for the late G1-through M-phase) or for 5-bromo-2'-deoxyuridine (BrdU; a marker for the S-phase)

101 Stereologic analyses of the number of 5-bromo-2'deoxyuridine (BrdU) -labeled cells revealed th

102 subsets through flow cytometric analysis of 5-bromo-2'deoxyuridine (BrdU) incorporation.

103 The rabbits were injected with 5-bromo-2-deoxyuridine (BrdU) 24-hours later and killed

104 ys (mean +/- SE), animals were injected with 5-bromo-2-deoxyuridine (BrDU) and 111In-Z2D3 F(ab')2.

105 are pulse labeled with the nucleotide analog 5-bromo-2-deoxyuridine (BrdU) and sorted into S-phase fr

106 e brain regions by injecting quail eggs with 5-bromo-2-deoxyuridine (BrdU) at various stages between

107 cted intraperitoneally (IP) with 50 mg/kg of 5-bromo-2-deoxyuridine (BrdU) immediately after anesthes

108 ng LN and recombinant TNF-alpha treatment by 5-bromo-2-deoxyuridine (BrdU) immunohistochemistry.

109 Cell-cycle progression was monitored by 5-bromo-2-deoxyuridine (BrdU) incorporation into the DNA

110 We used 5-bromo-2-deoxyuridine (BrdU) incorporation to examine D

111 onkeys (male Macaca fascicularis) were given 5-bromo-2-deoxyuridine (BrdU) injections 2-3 weeks after

112 roliferation indices were quantified using a 5-bromo-2-deoxyuridine (BrdU) labeling index.

113 alysed the incorporation of new nuclei using 5-bromo-2-deoxyuridine (BrdU) labelling by isolating ind

114 affic from the bone marrow to the DRGs using 5-bromo-2-deoxyuridine (BrdU) pulse, and serially measur

115 Rabbits (n = 32) were injected with 5-bromo-2-deoxyuridine (BrdU) to label a group of prolif

116 ure for DNA synthesis as measured by 24-hour 5-bromo-2-deoxyuridine (BrdU) uptake.

117 To identify proliferating cells, 5-bromo-2-deoxyuridine (BrDU) was administered over a pe

118 After 24 hours or 1 week of lens wear, 5-bromo-2-deoxyuridine (BrdU) was injected intravenously

119 Two hours before the animals were killed, 5-bromo-2-deoxyuridine (BrdU) was injected to detect S-p

120 dentate granule cells, single injections of 5-bromo-2-deoxyuridine (BrdU) with different survival ti

121 also proposed to retain DNA labels, such as 5-bromo-2-deoxyuridine (BrdU), either because they segre

122 ubgroup of animals also received intravenous 5-bromo-2-deoxyuridine (BrdU).

123 5-Bromo-2-deoxyuridine (BrdU, 50 mg/kg) was intraperiton

124 ed-thymidine autoradiographic techniques and 5-bromo-2;-deoxyuridine (BrdU) immunocytochemistry were

125 d sex differences in (a) cell proliferation (5'-bromo-2'-deoxyuridine [BrdU]), (b) neural precursor (

126 with markers for tumor proliferation (Ki67, 5-bromo-2'-deoxyuridine [BrdU]) and cell death (caspase-

127 sed a significant decrease in DNA synthesis (5-bromo-2-deoxyuridine [BrdU] uptake), an increase in DN

128 VEGF (>10 ng/ml) stimulated 5-bromo-2'-deoxyuridine (BrdUrd) incorporation into cell

129 d epidermis demonstrated a similar number of 5-bromo-2'-deoxyuridine (BrdUrd) S-phase cells as the co

130 , which associated with decreased numbers of 5-bromo-2'-deoxyuridine (BrdUrd)-positive cells in the p

131 Men1.rAd5 or control treatments, followed by 5-bromo-2-deoxyuridine (BrdUrd) in drinking water for fo

132 5-Bromo-2-deoxyuridine (BrdUrd) was administered to tumo

133 stemic exposure of 5-fluorouracil (FUra) and 5-bromo-2-deoxyuridine (BrdUrd).

134 suring both DNA content and incorporation of 5-bromo-2-deoxyuridine following in vivo pulse-labeling.

135 Animals received 5-bromo-2-deoxyuridine for 6 days.

136 Kinetic studies and short pulses of injected 5-bromo-2-deoxyuridine have been used to analyze the dev

137 r morphology, epithelial cell proliferation (5-bromo-2-deoxyuridine immunohistochemistry), apoptotic

138 Incorporation of 5-bromo-2-deoxyuridine in vivo increased in neurogenic a

139 of crypt cell DNA synthesis by detection of 5-bromo-2-deoxyuridine incorporated into the nuclei of c

140 5'-bromo-2'-deoxyuridine incorporation and annexin V sta

141 expressed retinoid receptors transiently and 5'-bromo-2'-deoxyuridine incorporation for labeling DNA-

142 S phase between 18 and 24 h as determined by 5'-bromo-2'-deoxyuridine incorporation, proliferating ce

143 with vehicle-treated cells as determined by 5'-bromo-2'-deoxyuridine incorporation.

144 ase in cellular DNA synthesis as measured by 5'-bromo-2'-deoxyuridine incorporation.

145 5-Bromo-2'-deoxyuridine incorporation and neo-endothelia

146 Furthermore, Tax-dependent stimulation of 5-bromo-2'-deoxyuridine incorporation and transcriptiona

147 were not growth arrested, as determined by a 5-bromo-2'-deoxyuridine incorporation assay.

148 5-ethynyl-2'-deoxyuridine and 5-bromo-2'-deoxyuridine incorporation assays were used t

149 Intratracheal transfer studies and 5-bromo-2'-deoxyuridine incorporation demonstrate that t

150 emonstrated, respectively, by the absence of 5-bromo-2'-deoxyuridine incorporation in hepatocytes, an

151 , we observed approximately 60% reduction of 5-bromo-2'-deoxyuridine incorporation in specific intrat

152 pericentral hepatocytes was demonstrated by 5-bromo-2'-deoxyuridine incorporation in the FGF19 trans

153 sed ribosomal protein S6 phosphorylation and 5-bromo-2'-deoxyuridine incorporation in wild-type but n

154 was accompanied by a significantly increased 5-bromo-2'-deoxyuridine incorporation rate in the same a

155 5-Bromo-2'-deoxyuridine incorporation was 25% in LPG but

156 Labeling indices for 5-bromo-2'-deoxyuridine incorporation were increased app

157 n D1, Cdk4, and cell proliferative activity (5-bromo-2'-deoxyuridine incorporation) in normal and ade

158 Proliferation was measured by 5-bromo-2'-deoxyuridine incorporation, [(3)H]thymidine i

159 a cell mass/pancreas, a two-fold increase in 5-bromo-2'-deoxyuridine incorporation, a four-fold incre

160 Cellular proliferation was evaluated with 5-bromo-2'-deoxyuridine incorporation, and cell size ass

161 omparison of mitotic indices, as measured by 5-bromo-2'-deoxyuridine incorporation, confirmed that hu

162 rambled vector) treatments, as determined by 5-bromo-2'-deoxyuridine incorporation, Ki-67 staining an

163 5-Bromo-2'-deoxyuridine incorporation, proliferating cel

164 than DLD-1-V tumors as determined by in vivo 5-bromo-2'-deoxyuridine incorporation.

165 identifying newly generated B cells through 5-bromo-2'-deoxyuridine incorporation.

166 Proliferation was quantified by 5-bromo-2'-deoxyuridine incorporation.

167 Proliferation was assessed by 5-bromo-2'-deoxyuridine incorporation.

168 ular DNA synthesis was analysed by assessing 5-bromo-2'-deoxyuridine incorporation.

169 decreased their proliferation as measured by 5-bromo-2'-deoxyuridine incorporation.

170 d G(2)-M cell cycle transition and decreases 5-bromo-2'-deoxyuridine incorporation.

171 This proliferative response was confirmed by 5-bromo-2'-deoxyuridine incorporation.

172 Our studies, by using 5-bromo-2-deoxyuridine incorporation and the Feulgen tec

173 ls during acute infection, but the degree of 5-bromo-2-deoxyuridine incorporation by both the CD4 T c

174 dies demonstrated increased growth rates and 5-bromo-2-deoxyuridine incorporation for HGF fibroblasts

175 5-Bromo-2-deoxyuridine incorporation studies indicated a

176 dentate gyrus of adult mice, as assessed by 5-bromo-2-deoxyuridine incorporation, but did not influe

177 Eltrombopag neither led to increased 5-bromo-2-deoxyuridine incorporation, decreased apoptosi

178 senescence-associated beta-galactosidase and 5-bromo-2-deoxyuridine incorporation, in normal but not

179 w cytometry, Ki-67 immunohistochemistry, and 5-bromo-2-deoxyuridine incorporation.

180 vely proliferating neuroblasts identified by 5-bromo-2;-deoxyuridine incorporation that nevertheless

181 (1) phase of the cell cycle, decreased BrdU (5-bromo-2'-deoxyuridine) incorporation, and led to incre

182 Pulse-labeling experiments using 5-bromo-2-deoxyuridine indicate that culture at 38 degre

183 lt mice, the labeling of dividing cells with 5-bromo-2'-deoxyuridine indicated that all Bax-positive

184 wed strong nuclear staining for incorporated 5-bromo-2'deoxyuridine, indicating active cell prolifera

185 cytes colocalized with nestin, vimentin, and 5-bromo-2-deoxyuridine, indicating that these cells are

186 The 5-bromo-2'-deoxyuridine injections were administered eve

187 cal and electrophysiological measures; BrdU (5-bromo-2-deoxyuridine) injections were used to quantify

188 by ELISA which measured the incorporation of 5-bromo-2'-deoxyuridine into DNA.

189 le control genes, increased incorporation of 5-bromo-2'-deoxyuridine into hepatocyte nuclei, and hepa

190 also to cause a massive dispersion of BrdU (5-bromo-2'-deoxyuridine)-labeled neuroblasts into surrou

191 ated kinase 1/2-, nuclear beta-catenin-, and 5-bromo-2'-deoxyuridine-labeled cells and altered kerati

192 and beta1 integrin retarded the migration of 5-bromo-2'-deoxyuridine-labeled mouse cerebellar granule

193 to identify the phenotype of newborn cells (5-bromo-2'-deoxyuridine-labeled) with various cellular m

194 wn by proliferating cell nuclear antigen and 5-bromo 2'-deoxyuridine labeling studies and, in unpubli

195 showed that there was a significant rise in 5-bromo-2' deoxyuridine labeling index 2-3 days after ir

196 5-Bromo-2'-deoxyuridine labeling and increases of graft

197 5-Bromo-2'-deoxyuridine labeling experiments demonstrate

198 uterus was determined by measuring both the 5-bromo-2'-deoxyuridine labeling index and the uterine w

199 glandular cells was determined according to 5-bromo-2'-deoxyuridine labeling indices, and their effe

200 5-Bromo-2'-deoxyuridine labeling reveals that cyst-linin

201 rom each group were sacrificed after in vivo 5-bromo-2'-deoxyuridine labeling to detect cells in S ph

202 er of transitional B cells, as determined by 5-bromo-2'-deoxyuridine labeling, and restored follicula

203 differentiation of OCPs were assessed using 5-bromo-2'-deoxyuridine labeling, annexin V staining, an

204 mal and medial cell replication, measured by 5-bromo-2'-deoxyuridine labeling, was significantly incr

205 apid rate of turnover in vivo as assessed by 5-bromo-2'-deoxyuridine labeling.

206 5-Bromo-2'-deoxyuridine-labeling experiments suggest tha

207 density (number of hepatocytes/unit volume), 5-bromo-2'-deoxyuridine-labeling index for analysis of c

208 5-Bromo-2'-deoxyuridine-labeling studies indicate that t

209 Since liver NK1.1+ T cells incorporate 5-bromo-2'-deoxyuridine more rapidly than thymic NK1.1+

210 in vitro and decreased the number of BrdU+ (5-bromo-2'-deoxyuridine+) myocytes detected at the infar

211 and 3) impaired posttraumatic neurogenesis (5-bromo-2-deoxyuridine + NeuN-positive cells).

212 Z), as observed using doublecortin (DCX) and 5-Bromo-2'-deoxyuridine/Neuronal nuclear protein (BrdU/N

213 roliferation rate was analyzed measuring the 5-bromo-2'-deoxyuridine nucleotide uptake.

214 pothesis by using injections of either BrdU (5-bromo-2'-deoxyuridine) or 3H-thymidine into homozygous

215 Neuronal injury and neurogeneration (5-bromo-2-deoxyuridine positive neurons) were quantified

216 In addition, there were fewer 5-bromo-2'-deoxyuridine-positive cells in the LK populat

217 PMA also induced a 33% decrease in 5-bromo-2'-deoxyuridine-positive CFs, which was inhibite

218 vitro using a combination of immunostaining, 5-bromo-2'-deoxyuridine proliferation assays, and histol

219 enomas were noted only in male mice, whereas 5-bromo-2'-deoxyuridine proliferation indices were marke

220 ferating cell nuclear antigen, cyclin A, and 5-bromo-2-deoxyuridine reveals that cyclin E promotes pr

221 Studies using the cell proliferation marker 5-bromo-2'-deoxyuridine show that localized degeneration

222 Green fluorescent protein and 5-bromo-2'-deoxyuridine staining indicated that persiste

223 ased hepatocyte proliferation as measured by 5-bromo-2'-deoxyuridine staining.

224 hanges were assessed by light microscopy and 5-bromo-2'-deoxyuridine staining; flow cytometry was use

225 as characterized by flow cytometry and BrdU (5-bromo-2-deoxyuridine) staining following synchronizati

226 immunoreactive cells also were costained for 5-bromo-2'-deoxyuridine, suggesting their re-entry into

227 bone marrow at birth and by incorporation of 5-bromo-2'-deoxyuridine, they appear to be a dynamic pop

228 e chain reaction and used the mitotic marker 5-bromo-2'-deoxyuridine to analyze adult neurogenesis.

229 Using propidium iodide to label nuclei and 5-bromo-2'-deoxyuridine to monitor proliferation, we fou

230 lation of megakaryocytes exhibiting enhanced 5-bromo-2'-deoxyuridine uptake and increased expression

231 reduced proliferation as indicated by lower 5-bromo-2'-deoxyuridine uptake, increased apoptosis, and

232 show that (a) proliferation, as measured by 5-bromo-2'-deoxyuridine uptake, is higher in the LN than

233 9% of control mice (P>0.05), but the rate of 5-bromo-2-deoxyuridine uptake was greater, suggesting a

234 pendix estimated by in vivo incorporation of 5-bromo-2'deoxyuridine was more than two times that of P

235 nuclear antigen and by the incorporation of 5-bromo-2'-deoxyuridine, was determined to be approximat